All drugs should be compounded under suitable quality standards, but who should be ensuring those standards among traditional compounders and outsourcing facilities was debated at the House Energy and Commerce Subcommittee on Health.
In written testimony, FDA Commissioner Scott Gottlieb, MD, cited a litany of manufacturing problems at compounding facilities, including mold contamination of the type that caused lethal fungal infections during the New England Compounding Center